ES2193007T1 - Formulacion farmaceutica estable que comprende la modificacion ii de torsemida. - Google Patents

Formulacion farmaceutica estable que comprende la modificacion ii de torsemida.

Info

Publication number
ES2193007T1
ES2193007T1 ES01911078T ES01911078T ES2193007T1 ES 2193007 T1 ES2193007 T1 ES 2193007T1 ES 01911078 T ES01911078 T ES 01911078T ES 01911078 T ES01911078 T ES 01911078T ES 2193007 T1 ES2193007 T1 ES 2193007T1
Authority
ES
Spain
Prior art keywords
pharmaceutical formulation
stable pharmaceutical
torsemida
torsemide
includes modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES01911078T
Other languages
English (en)
Other versions
ES2193007T3 (es
Inventor
Minutza Leibovici
Ruth Tenengauzer
Mira Kopel
Judith Aronhime
Marco Kordova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27359046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2193007(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of ES2193007T1 publication Critical patent/ES2193007T1/es
Application granted granted Critical
Publication of ES2193007T3 publication Critical patent/ES2193007T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formulación farmacéutica estable que comprende una cantidad efectiva de torsemida y un portador farmacéuticamente aceptable, caracterizada porque la torsemida es la modificación II de torsemida que no experimenta conversión significativa en otras formas polimórficas de torsemida cuando se almacena durante por lo menos 3 meses a 40ºC y con una humedad relativa del 75%.
ES01911078T 2000-02-17 2001-02-21 Formulacion farmaceutica estable que comprende la modificacion ii de la torsemida. Expired - Lifetime ES2193007T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18328800P 2000-02-17 2000-02-17
US09/789,424 US6482417B2 (en) 2000-02-17 2001-02-21 Stable pharmaceutical formulation comprising torsemide modification II
PCT/US2001/005577 WO2002067935A1 (en) 2000-02-17 2001-02-21 A stable pharmaceutical formulation comprising torsemide modification ii

Publications (2)

Publication Number Publication Date
ES2193007T1 true ES2193007T1 (es) 2003-11-01
ES2193007T3 ES2193007T3 (es) 2004-11-01

Family

ID=27359046

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01911078T Expired - Lifetime ES2193007T3 (es) 2000-02-17 2001-02-21 Formulacion farmaceutica estable que comprende la modificacion ii de la torsemida.

Country Status (20)

Country Link
US (1) US6482417B2 (es)
EP (1) EP1292303B1 (es)
JP (1) JP2004522780A (es)
CN (1) CN1505512A (es)
AT (1) ATE266404T1 (es)
CA (1) CA2410802A1 (es)
DE (2) DE1292303T1 (es)
DK (1) DK1292303T3 (es)
ES (1) ES2193007T3 (es)
HR (1) HRP20030762A2 (es)
HU (1) HUP0600143A2 (es)
IL (1) IL157539A0 (es)
IS (1) IS6919A (es)
MX (1) MXPA03007908A (es)
NO (1) NO20033699L (es)
PT (1) PT1292303E (es)
SI (1) SI1292303T1 (es)
SK (1) SK11632003A3 (es)
TR (1) TR200401462T4 (es)
WO (1) WO2002067935A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
ITMI20020639A1 (it) * 2002-03-27 2003-09-29 Cosma S P A Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea
EP1686960A4 (en) * 2003-10-28 2007-03-07 Glaxo Group Ltd INHALABLE PHARMACEUTICAL PREPARATIONS EMPLOYING LACTOSE ANHYDRATE, AND METHODS OF ADMINISTERING SAID PREPARATIONS
ES2244324B1 (es) * 2004-03-25 2006-11-16 Ferrer Internacional, S.A. Composiciones diureticas de liberacion prolongada.
CN100421662C (zh) * 2005-11-08 2008-10-01 周卓和 托拉塞米分散片及其制备方法和应用
CN100372534C (zh) * 2006-04-20 2008-03-05 南京海辰药业有限公司 托拉塞米冻干制剂及制备方法
US20080213362A1 (en) * 2007-02-02 2008-09-04 Lawrence Solomon Compositions and methods using torsemide
CN106038500A (zh) * 2016-05-26 2016-10-26 南京正科医药股份有限公司 一种托拉塞米片

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1477664A (en) * 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
DE3529529A1 (de) 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
CN1090935C (zh) * 1995-02-28 2002-09-18 阿温蒂斯药物公司 哌啶子基烷醇化合物的药物组合物
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
MXPA02001369A (es) * 1999-08-11 2005-08-26 Teva Pharma Torasemidas polimorfas.

Also Published As

Publication number Publication date
SI1292303T1 (en) 2004-10-31
US6482417B2 (en) 2002-11-19
PT1292303E (pt) 2004-09-30
DE1292303T1 (de) 2003-09-18
NO20033699L (no) 2003-10-10
CN1505512A (zh) 2004-06-16
DE60103276T2 (de) 2005-06-23
DK1292303T3 (da) 2004-09-06
DE60103276D1 (de) 2004-06-17
JP2004522780A (ja) 2004-07-29
EP1292303B1 (en) 2004-05-12
TR200401462T4 (tr) 2004-08-23
CA2410802A1 (en) 2002-09-06
ES2193007T3 (es) 2004-11-01
SK11632003A3 (sk) 2004-04-06
IL157539A0 (en) 2004-03-28
MXPA03007908A (es) 2004-12-06
NO20033699D0 (no) 2003-08-20
IS6919A (is) 2003-08-20
WO2002067935A1 (en) 2002-09-06
HUP0600143A2 (en) 2006-10-28
ATE266404T1 (de) 2004-05-15
EP1292303A1 (en) 2003-03-19
EP1292303A4 (en) 2003-07-09
HRP20030762A2 (en) 2005-08-31
US20020035135A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
DE69907977D1 (de) Pyrrolobenzodiazepine
EE201000018A (et) Ravimkompositsioonid, mis p?hinevad antikolinergiliselt toimivatel henditel ja
MY129356A (en) Electrospun pharmaceutical compositions
BR9303469A (pt) Conjugado de interferon,composto,processo de preparacao de um conjugado de interferon,use e composicoes farmaceuticas
ATE113650T1 (de) Ausgewählte stämme von lactobacillus enthaltende pharmazeutische zusammensetzungen.
BR0109943A (pt) Composições farmacêuticas
SE8700499D0 (sv) Novel pharmacologically active compounds
AR066982A2 (es) Compuestos heteroaromaticos sustituidos como inhibidoress tirosin quinasa, composiciones farmaceuticas que los contiene y su uso en la preparacion de medicamentos
RU2002109814A (ru) Новые производные аминодикарбоновых кислот, обладающие фармацевтическими свойствами
ES2178036T3 (es) Derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que le contienen.
EA200200812A1 (ru) Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение
DE69115263D1 (de) Pharmazeutische zusammensetzungen.
ES2054379T3 (es) Formas farmaceuticas orales de pimobendano.
ES2193007T1 (es) Formulacion farmaceutica estable que comprende la modificacion ii de torsemida.
ATE478662T1 (de) Arzneilösungen enthaltend modafinilverbindungen
NO990440L (no) Preparat som innbefatter mupirocin og klorheksidin
ES2105605T3 (es) Antagonistas de taquiquinina, su preparacion y utilizacion en formulaciones farmaceuticas.
NO20040702L (no) Kombinerte preparater som inneholder 1,4-benzotiepin-1,1-dioksidderivater og andre aktive substanser og anvendelsen derav
ATE316376T1 (de) Neue pharmazeutische zusammenstellung und deren herstellungsprozess
ATE259638T1 (de) Nicht-festes topisch anzuwendendes arzneimittel enthaltend glyzerol und alchemilla vulgaris extrakt
ITMI20000293A0 (it) Derivati del 3,9-diazabiciclo [3.3.1]nonano ad attivita' analgesica
ES2179302T3 (es) Formas galenicas y sus utilizaciones.
ITRE920048U1 (it) Struttura di pennello
IT9048066A0 (it) 2- amminotetraline-6, 7-sostituite attive come immunomodulanti e composizioni farmaceutiche che le contengono.
ATE300486T1 (de) Tablettenspender